Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, announced that Health Canada has approved Seasonique. Seasonique is a next generation extended-cycle oral contraceptive for the prevention of pregnancy. Seasonique is manufactured by Duramed Pharmaceuticals, Inc., a wholly owned subsidiary of Pharmaceutical Industries Ltd.
Under the Seasonique extended-cycle regimen, women take active tablets of 0.15 mg levonorgestrel/0.03 mg of ethinyl estradiol for 84 consecutive days, followed by seven days of a low dose of ethinyl estradiol (0.01 mg). The regimen is designed to reduce the number of withdrawal bleeding periods from thirteen to four periods per year.
"The approval of Seasonique is great news for Canadian women. Now women have an additional extended-cycle oral contraceptive from which to reduce the number of menstruations from thirteen to four per year", said Jonathan Ross Goodman, president & CEO Paladin Labs.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products.